OcuNexus Therapeutics Stock

ocunexus.comBioTechFounded: 1900Funding to Date: $144.36MM

Ocunexus Therapeutics is a biotechnology company focused on inflammasome modulation for treatment of Dry Age-related Macular Degeneration and Diabetic Retinopathy.

Register for Details

For more details on financing and valuation for OcuNexus Therapeutics, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Team

Management Team

Brian Levy
Chief Executive Officer
David Pool
Chief Financial Officer
Tracey Sunderland
Chief Operating Officer
Anthony Phillips Ph.D
Medical & Pre-Clinical Consultant
Colin Green Ph.D
Scientific Co-Founder & Advisor
Bradford Duft JD
Co-Founder, President & Board Member
David Becker Ph.D
Scientific Co-Founder

Board Members

Bradford Duft JD
Frank Spurway
Geoffrey Brooke MD
GBS Venture Partners
Howard Greene
Inna Eitan
RusnanoMedInvest
James Blair Ph.D
Domain Associates
James Mervis JD
Mikhail Getman Ph.D
RusnanoMedInvest
Rajiv Shukla

Other companies like OcuNexus Therapeutics in the BioTech sector

Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.89B
Sector
Last Round Est. Valuation
$872.62MM
Sector
Last Round Est. Valuation
$486.63MM
Sector
Last Round Est. Valuation
$186.12MM
Sector
Last Round Est. Valuation
$50.4MM
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$185MM